Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsMYGN -0.87%42 14-Day RSI is 61.41 as of Sep. 22, 2026. GuruFocus rates MYGN with a GF Score™ of 42/100 and a GF Value™ of $11.35 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 82.57% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-09-22), Myriad Genetics's 14-Day RSI is 61.41.
The industry rank for Myriad Genetics's 14-Day RSI or its related term are showing as below:
MYGN's 14-Day RSI is ranked worse than 82.57% of 218
companies
in the Medical Diagnostics & Research industry
Industry Median: 48.42
vs MYGN: 61.41
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Myriad Genetics 14-Day RSI Related Terms
MYGN vs BDSX, XGN, IMDX: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (MYGN) has a 14-Day RSI of 61.41 as of Sep. 22, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #180 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 82.6%.
Is Myriad Genetics' 14-Day RSI too high?
Myriad Genetics' current 14-Day RSI is 61.41. The Medical Diagnostics & Research industry median 14-Day RSI is 48.42. Myriad Genetics' value of 61.41 is 26.8% above this industry median. Based on the distribution chart, Myriad Genetics ranks #180 out of 218 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' 14-Day RSI compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #180 out of 218 companies for 14-Day RSI. This places Myriad Genetics in the lower half of its industry. The industry median 14-Day RSI is 48.42. Myriad Genetics' value of 61.41 is 26.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 48.42, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current 14-Day RSI of 61.41 is 26.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 48.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current 14-Day RSI is 61.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (MYGN) is currently considered Possible Value Trap. The stock's GF Value™ is $11.35, compared to a current price of $3.98 — trading 65% below its estimated fair value. The current 14-Day RSI is 61.41 and 26.8% above the Medical Diagnostics & Research industry median of 48.42. Myriad Genetics' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Myriad Genetics (MYGN), the current 14-Day RSI is 61.41 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (MYGN) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of $3.98 is trading 65% below its estimated GF Value™ of $11.35.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for MYGN:
14-Day RSI: 61.41
GF Value™: $11.35 vs. price of $3.98 (65% below fair value)
Industry Position: 26.8% above the Medical Diagnostics & Research median (#180 of 218)
No single metric tells the full story. See the MYGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc. is a US-based molecular diagnostics company that develops and commercializes genetic and genomic tests used across oncology, women's health, and mental health. Its portfolio includes hereditary cancer risk tests such as MyRisk and BRACAnalysis, tumor profiling and companion diagnostics including MyChoice CDx and Precise Tumor, the Prolaris prostate cancer test, the GeneSight pharmacogenomic test for depression and other psychiatric conditions, and the SneakPeek early fetal sex determination test. These tests are ordered by physicians, hospitals, health systems, and payers, and are used to assess disease risk, guide treatment selection, and inform reproductive decisions. Myriad generates revenue primarily through third-party reimbursement from insurers and government payers, along with direct patient billing. The company operates mainly in the United States, which accounts for the large majority of its revenue, and also sells in selected international markets.
42GF Score
Get the complete analysis for MYGN
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYGN has been successfully added to your 
